Biotech
Commented by Nico Popp on April 4th, 2023 | 17:04 CEST
Race against cancer: BioNTech, Bayer, Defence Therapeutics
BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.
Read
Commented by Nico Popp on March 27th, 2023 | 09:26 CEST
Cost pressure in the healthcare system - how you benefit: Bayer, BioNxt, BioNTech
What do you think of the German healthcare system? While doctors regularly grumble about bureaucracy and patients about long waiting times or other inconsistencies, a new divide is opening up between pharmaceutical companies. Research-based pharmaceutical companies favour long patent protection, while generics manufacturers want more lax rules. We explain the system and highlight opportunities for investors.
Read
Commented by Juliane Zielonka on March 23rd, 2023 | 08:02 CET
BioNxt Solutions, Bayer, BioNTech - These pharma stocks offer growth potential
The risk of cancer is increasing worldwide for people over the age of 50. The reasons for this are lack of sleep and exercise, pre-existing diseases and poor nutrition. It has now also been scientifically proven that permanent stress is a cause of Parkinson's disease. According to the WHO, disabilities and deaths due to Parkinson's are increasing faster worldwide than for any other neurological disease. Pharmaceutical and biotech companies are doing everything they can to improve the quality of life of those affected. The Canadian biotech company BioNxt is working on a comparative study to improve a therapy patch for treating Parkinson's and make accompanying drug products scalable. Bayer subsidiary Bluerock Therapeutics is using data from the Apple Watch to research Parkinson's symptoms. And CEO Uğur Şahin of BioNTech has closed a billion-dollar deal in cancer therapy.
Read
Commented by Stefan Feulner on March 20th, 2023 | 09:37 CET
Evotec, Defence Therapeutics, Morphosys - Movement in the biotech sector
Is a new wave of takeovers starting in the biotech sector? Already last year, acquisitions by Big Pharma were expected to increase, but these largely failed to materialize. However, this could accelerate in the current year. On the one hand, pharmaceutical companies, such as vaccine manufacturer Pfizer, have deep pockets and need new innovations for their product portfolio; on the other hand, second-tier stocks are attractive targets due to the strong correction.
Read
Commented by Fabian Lorenz on March 16th, 2023 | 11:51 CET
Takeover speculation at Defence Therapeutics! What are BioNTech, Morphosys, and Evotec doing?
Defence Therapeutics is one of the biotech high flyers of the past months. The share has more than doubled since October. And this could be just the beginning. Operationally, things are going well, a strong partner has been acquired, and experts are speculating about a takeover. And what are the German biotechs doing? At BioNTech, it will be exciting at the end of March, because the Mainz-based company needs new blockbusters. At Morphosys, analysts recently saw further downside potential. Will a new management board bring about a turnaround? Evotec also had little positive to report. However, an AI investment in the hype surrounding ChatGPT is making headlines.
Read
Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET
Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!
The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!
Read
Commented by André Will-Laudien on March 10th, 2023 | 10:15 CET
Defeat cancer! Defence Therapeutics, BioNTech, Morphosys, Bayer - These biotechs are close
The listed biotechnology sector has entered a strong correction phase since the COVID-19 pandemic mode ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Compounding the problem for companies is the significant increase in interest rates for long-term financing. The segment relies on revolving investor capital, but the corresponding risk parameters have been adjusted upward, making some refinancings extremely expensive. Costs are rising, which is leading to renewed price markdowns. However, some companies are convincing through their innovative strength and have recently outperformed the market. We take a closer look at the blockbuster stocks.
Read
Commented by Fabian Lorenz on March 9th, 2023 | 10:52 CET
BioNTech, Pfizer, Bayer and BioNxt Solutions on the biotech takeover merry-go-round
2023 could become the year of takeovers in the pharmaceutical and biotech sectors. This is what the experts at PwC expect. Thus, at the JP Morgan industry conference in San Francisco, not only were takeover candidates discussed but billion-dollar transactions were reported. One reason is the Inflation Reduction Act in the USA. This allows negotiations on drug prices. To prevent sales declines, Big Pharma must invest in new top sellers. And it is already doing so. The latest takeover rumor comes from BioNTech partner Pfizer. At BioNTech, the negative news currently outweighs the positive. Whether Bayer will take action with the boss or be taken over itself is not yet entirely clear. But there are also opportunities for investors in the smallcap sector. Take BioNxt Solutions, for example - the Canadian company with its operational focus in Germany recently secured new patents, and the share price has jumped.
Read
Commented by Stefan Feulner on March 1st, 2023 | 14:01 CET
BioNTech, BioNxt Solutions, Bayer - Turn of the tide
Just how fundamental biotechnology already is for humanity was demonstrated by the development of the various COVID vaccines, which was extremely rapid by historical standards. Previously unknown companies such as BioNTech, Valneva and CureVac came into the focus of the stock market and were able to multiply within a very short time. Even after the pandemic has ended, research in the biotech sector is running at full speed. This is giving rise to new, innovative growth companies that could follow a similar trajectory in the future.
Read
Commented by André Will-Laudien on February 14th, 2023 | 15:54 CET
Election winners in the fight against cancer! Bayer, Defence Therapeutics, Formycon, Valneva - 300% rises are possible!
In 2021, 18.7 million people received the shocking diagnosis of "cancer". Current trends, unfortunately, suggest that this number will continue to rise in the coming years. Thanks to growing research successes, however, there is hope that biotechnology will make it much more likely that sufferers will survive. It is a matter of developing suitable active substances or launching modern therapies. Recently, mRNA technology has also been making a name for itself in cancer prevention. Innovative biotech companies are back on the radar of risk-conscious investors. Which shares are currently in the spotlight?
Read